Status:
TERMINATED
Muscle, Essential Amino Acids, and eXercise in Heart Failure
Lead Sponsor:
Arizona State University
Collaborating Sponsors:
Mayo Clinic
Conditions:
Heart Failure, Diastolic
Eligibility:
All Genders
60+ years
Phase:
NA
Brief Summary
Half of heart failure patients have preserved ejection fraction (HFpEF). Like patients with reduced ejection fraction (HFrEF), HFpEF patients suffer from exercise intolerance (low VO2max), which reduc...
Eligibility Criteria
Inclusion
- Age 60+ years of age
- Able to communicate meaningfully with the investigator and must be legally competent to provide written informed consent.
- Diagnosed with HFpEF as per established echocardiographic criteria (New York Heart Association Class II-III).
Exclusion
- Unstable angina, myocardial infarction in the past 4 weeks
- Uncompensated heart failure
- New York Heart Association class IV symptoms, complex ventricular arrhythmias, symptomatic severe aortic stenosis, acute pulmonary embolus, acute myocarditis, untreated high-risk proliferative retinopathy, recent retinal hemorrhage, uncontrolled hypertension, baseline blood screening abnormalities
- Medication non-compliance
- Medical / orthopedic conditions precluding exercise
- Exercise training (\>2 weekly sessions of moderate to high intensity aerobic or resistance exercise)
- Subjects on anti-coagulation medication will not be eligible for the muscle biopsy procedure, but are deemed eligible for study participation if INR \< 3.
Key Trial Info
Start Date :
September 19 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2018
Estimated Enrollment :
1 Patients enrolled
Trial Details
Trial ID
NCT03312387
Start Date
September 19 2017
End Date
December 31 2018
Last Update
September 3 2019
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Arizona State University
Phoenix, Arizona, United States, 85004
2
Mayo Clinic Arizona
Scottsdale, Arizona, United States, 85259